The FDA has granted accelerated approval to AstraZeneca's Etcamah (camizestrant), used with a CDK 4/6 inhibitor, for breast cancer.

The FDA has so far approved four botanical products, with a view to greenlight more. Credit: Svetliy/Shutterstock.com. The US Food and Drug Administration (FDA) is requesting public input on both the ...

Ionis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease “in the coming weeks”.

Dravet syndrome is described as a rare lifelong neurological disorder marked by frequent, often treatment-resistant seizures from infancy. Credit: one photo / Shutterstock.com. Médunik Canada has ...

At ESC 2026, a session presented by Dr Domenica Rubino covered the considerations to take into account when comparing oral and injectable formulations of GLP-1 therapies.

GSK’s deal with HUTCHMED marks the latest in a long line of licensing activities between Western pharma companies and Chinese drug developers. Credit: testing/Shutterstock.com. GSK will pay a ...

Typewriter harnesses a non-viral approach as viral vectors increasingly come under the spotlight for their associated safety risks.

The licensed VHH antibody molecule originates from RenNano, Biocytogen’s technology designed to identify fully human VHH antibodies. Credit: Anamaria Mejia / Shutterstock.com. China-based Biocytogen ...

Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of subcutaneous drug formulations using Alteogen’s ALT-B4 technology.

The FDA's latest efforts to curb the illicit US medicines trade are primarily centred around weight loss and fat-reducing peptides.

An explosion in the popularity of peptides is fueling a wave of technical innovation and unlicensed supply, with regulators playing catch-up. Credit: PiyaZIrconplus ...